Login to Your Account

Apollo bid lands phase III win in ATTR, safety to eclipse Ionis drug?

By Randy Osborne
Staff Writer

Wednesday, September 20, 2017

Solid efficacy and a distinguishing safety profile – so far, anyway – should give Alnylam Pharmaceuticals Inc. and Sanofi SA an edge over competitor Ionis Pharmaceuticals Inc., analysts said, as the partnered pair scored a top-line phase III win testing RNAi therapy patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription